TG Therapeutics Q3 2026: Briumvi target raised again, but sales growth slows to 2% from Q2
Did the story change? Mostly unchanged
Not much. US sales of Briumvi, TG's multiple sclerosis drug, were $232.6 million, up 52% from a year earlier but only 2% from Q2, and TG raised its 2026 US target for the third time, to $915–920 million, which implies about $260–265 million in Q4. The shares fell as much as about 9% in the morning but closed up 5.9%, at their highest close in at least five years.
What it means
- What changed
- TG's 2026 US Briumvi target rose to $915–920 million from $890–905 million, and total revenue to about $1 billion.
- What hasn't changed
- Briumvi is still TG's only approved product, and the under-the-skin version's Phase 3 results are still due around year-end or early 2027.
- Next · Year-end 2026 or early 2027
- Phase 3 results for an under-the-skin version of Briumvi, dosed every three months.
Closing prices: $63.38 on Nov 9, 2026 (Yahoo Finance, CNBC) and $59.83 on Nov 6 (Nasdaq, Yahoo Finance).
Snapshot at the Nov 6, 2026 close
- Market value
- $9.2B
- Enterprise value
- $9.3B
- Price/sales
- 11.5×
- EV/sales
- 11.6×
- P/E
- 20.7×*
- Price/FCF
- 526.8׆
- Revenue growth
- +76%
- FCF margin
- 2%†
- Net debt
- $133M
Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Aug 5, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $59.83 (Nasdaq historical close (Yahoo Finance)); 153.1 million shares (common shares on the cover page of the 10-Q filed Aug 5, 2026). n/m = not meaningful (e.g. negative earnings). * Trailing P/E includes a $340M income-tax benefit in the 12 months to Jun 30, 2026. † Free cash flow includes $6M of customer prepayments (increase in contract liabilities) in the 12 months to Jun 30, 2026.
TG’s only drug kept growing, and the company raised its full-year targets for the third time this year. The quarter’s growth was slower, though: US sales were barely higher than in Q2, so the raised target leans on the fourth quarter.
How the stock reacted
TG shares closed at $63.38 on Nov 9, up 5.9% from the Nov 6 close of $59.83 (Yahoo Finance, CNBC), after trading as much as about 9% lower in the morning. It was their highest close in at least five years, above the $61.63 of Nov 4 (Yahoo Finance, our calculation); the shares have roughly doubled this year. Earlier in the day Investing.com wrote that investors “may have focused more on the earnings miss than the sales beat”: profit per share was $0.35 against a consensus of $0.37 on Investing.com’s figures, while revenue beat. We found no report explaining the afternoon rebound.
Did the story change?
In August TG expected about $890–905 million of US Briumvi sales in 2026; it now expects $915–920 million. The table compares Q2 with Q3.
| Driver | Q2 → Q3 2026 | Management: before → now | Signal |
|---|---|---|---|
| US Briumvi sales | $227.7M → $232.6M (+2%; +52% from a year earlier) | 2026 target $890–905M (Aug 3) → $915–920M (Nov 9) | Better |
| Total revenue | $240.3M → $259.9M, including a $10M sales milestone from partner Neuraxpharm | About $950M for 2026 → about $1 billion | Better |
| Operating expenses, excluding stock pay | About $150M → about $107M, as manufacturing spending fell (CFO) | 2026 range $450–500M → reaffirmed | Unchanged |
| Net income | $7.8M → $55.5M ($0.05 → $0.35 a diluted share) | No profit guidance → none | Better |
| Cash and investments | $612.3M → $556.7M, after about $100M of share buybacks | Cash “sufficient to fund our business” → same wording | Unchanged |
Sources: Q2 and Q3 releases; the Nov 9 call (Investing.com transcript). Comparisons are our calculations from reported figures.
US Briumvi sales by quarter ($M)
Sales grew every quarter, but the step from Q2 to Q3 2026 was the smallest in the period shown.
Show the data table
| Quarter | Sales ($M) |
|---|---|
| Q3 2025 | 152.9 |
| Q4 2025 | 182.7 |
| Q1 2026 | 194.8 |
| Q2 2026 | 227.7 |
| Q3 2026 | 232.6 |
What got better
TG has raised its 2026 revenue guidance at each results date since May. It started 2026 at $825–850 million of US Briumvi sales and $875–900 million of total revenue; it now expects $915–920 million and about $1 billion. Chief executive Michael Weiss said TG is “on track to exceed $1 billion in global revenue in 2026”.
Demand signals reported on the call were strong. Chief commercial officer Adam Waldman said October was “a record for total BRIUMVI prescribers in a month”, that new patient starts accelerated “at the end of Q3 and continuing into Q4”, and that about a third of new patients still come from another drug of the same class.
TG also spent less. Excluding stock pay, operating expenses fell to about $107 million from about $150 million in Q2, when spending to make the under-the-skin version and a second manufacturer was unusually high, CFO Sean Power said.
What needs watching
The raised target needs a stronger finish. Waldman said TG had “expected second-half growth to be primarily driven by the fourth quarter”, and the new range implies “more than $260 million” of US sales in Q4, against $232.6 million in Q3.
Pricing is a question. Evercore ISI analyst Michael DiFiore said a competitor had described TG as gaining share “through aggressive contracting” that “is probably not sustainable”, and asked whether discounts would deepen in 2027. Waldman answered that TG’s contracting approach is “100% sustainable”. TG hasn’t given 2027 guidance.
The takeover talk hasn’t gone away, and none of it is confirmed. In November 2024 business reporter Dominic Walsh wrote on X of “vague whispers of bid interest”, with Roche the most talked about, TheFly reported; in August 2026 Betaville, a mergers and acquisitions blog, posted an “uncooked” (unverified) alert of interest from an unnamed suitor, Stocktwits reported. The Q3 release doesn’t mention a sale, and in the call transcript we read, no analyst asked about one and management didn’t raise it; Weiss said TG is “committed to being disciplined with the capital we are generating.”
The 10-Q, filed after the close on Nov 9, adds two details. Q3 revenue included $5.0 million from Neuraxpharm, its share of development costs for the single-infusion start to Briumvi, which it opted in to during the quarter; with the $10 million milestone, partner payments account for most of the $19.6 million rise in total revenue from Q2, while product sales rose $4.2 million. And from Sep 29 some of the drug substance and finished product TG imports from its contract manufacturers became subject to a 15% US tariff; based on current tariffs, TG says it doesn’t expect a material effect on its overall gross margin.
Does this change the long-term story?
Our read: no. Briumvi is growing and TG keeps raising its targets, but it is still a one-drug company, and the next big test is the under-the-skin version’s Phase 3 results around the turn of the year, with TG targeting a potential launch in 2028.
Notes
- Growth (our calculation): $232.6M ÷ $227.7M − 1 = 2.2%; $232.6M ÷ $152.9M − 1 = 52.1%. Total revenue: $259.9M ÷ $161.7M − 1 = 60.7%.
- Q2 → Q3 revenue (10-Qs; our calculation): total $240.3M → $259.9M (+$19.6M); product revenue $235.8M → $240.0M (+$4.2M); license, milestone, royalty and other revenue $4.5M → $19.9M (+$15.4M), including the $10.0M milestone and $5.0M of license revenue.
- Q4 implied by the target (our calculation): $915–920M − nine-month US sales of $655.1M = $259.9–264.9M.
- Price change: $63.38 ÷ $59.83 − 1 = +5.9%; intraday low $54.61 (−8.7%, Yahoo Finance). The shares closed at $30.10 at the end of 2025 (Yahoo Finance); $63.38 ÷ $30.10 − 1 = +110.6%.
- Q2 2026 net income: $7.8M, $0.05 a diluted share (Q2 release). Q3 2025 net income of $390.9M included a one-off tax benefit of about $365M, so the year-on-year comparison isn’t meaningful.
What to watch next
- Year-end 2026 or early 2027
- Topline Phase 3 results for under-the-skin Briumvi; TG targets a launch in 2028.
- Early 2027 (expected)
- Fourth-quarter results: whether US Briumvi sales reached the roughly $260–265 million implied by the raised target.
- Mid-2027
- A label update for a one-infusion start to Briumvi treatment, which TG expects after the ENHANCE trial.
Quick questions
What is Briumvi?
TG's only approved drug, an infusion for relapsing forms of multiple sclerosis. It targets CD20 on B cells, a type of immune cell, like Roche's Ocrevus and Novartis's Kesimpta.
What is gross-to-net?
The gap between a drug's list price and what the company keeps after discounts and rebates to insurers, government programs and others. An analyst on the call said TG had guided to it averaging about 65% this year.
Updates
- : Updated with the 10-Q, filed after the close on Nov 9: Q3 revenue also included a $5.0 million payment from partner Neuraxpharm, and some of TG's imported drug supply became subject to a 15% US tariff from Sep 29.
- : Updated to the Nov 9 close: the shares closed up 5.9% at $63.38 after falling as much as about 9% in the morning; an earlier version gave the early-afternoon price, down 5.8%.
About TG Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)
+ 6 more
Accessed Nov 1, 2026: TheFly (TipRanks): reporter's posts on bid interest, Nov 13, 2024 · Stocktwits: buyout rumours, Aug 21, 2026
Accessed Nov 9, 2026: TG Therapeutics: Q1 2026 results (SEC 8-K) · TG Therapeutics: Q4 2025 results and 2026 guidance (SEC 8-K) · TG Therapeutics: Q3 2025 results (SEC 8-K)
Accessed Nov 10, 2026: TG Therapeutics: 10-Q for the quarter to Sep 30, 2026
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.